Molina Healthcare (MOH) Earnings Date & Reports

Key Takeaways

• Molina Healthcare reported third-quarter 2026 adjusted earnings of $0.89 per share, topping the FactSet consensus estimate of $0.79 by $0.10.
• Total revenue came in at $11.08 billion, above the $10.86 billion consensus, though it declined 3.4% from $11.48 billion a year earlier.
• GAAP net income fell 52% to $38 million, or $0.73 per share, from $79 million, or $1.51 per share, in the prior-year quarter, reflecting higher medical costs.
• Management reaffirmed full-year 2026 adjusted EPS guidance of $5.25 and held premium revenue guidance at roughly $42 billion.
• Total membership continued to shrink, driven by a steep decline in Marketplace enrollment, while the consolidated medical care ratio rose year over year.
• The stock slipped roughly 5.5% after the release as investors weighed the headline beat against ongoing margin pressure.

Earnings Context and Why It Matters

Molina Healthcare is one of the largest Medicaid-focused managed care organizations in the United States, which makes its quarterly results a closely watched barometer for government-sponsored health insurance. The company has spent the past several quarters contending with falling enrollment following the end of pandemic-era Medicaid protections, alongside elevated medical costs. This quarter was important because investors were looking for evidence that Molina's margin challenges are stabilizing and that its planned 2027 recovery remains on track. With the stock trading well above its 52-week low, the market had already begun pricing in a rebound, making the details of this report especially significant for the outlook.

Reported Results

Molina Healthcare reported third-quarter 2026 adjusted earnings of $0.89 per share, exceeding the FactSet consensus estimate of $0.79 per share. Total revenue of $11.08 billion also topped the $10.86 billion consensus. On a GAAP (generally accepted accounting principles) basis, however, net income fell 52% to $38 million, or $0.73 per share, compared with $79 million, or $1.51 per share, in the same period last year. Adjusted net income was $46 million.

The decline reflects a meaningful contraction in the business. Premium revenue of approximately $10.46 billion fell about 4% year over year as membership shrank. The consolidated MCR (medical care ratio, which measures medical costs as a percentage of premium revenue) rose year over year, and the company's Medicaid segment, its largest, also saw its MCR climb. Total ending membership declined to roughly 4.86 million from about 5.63 million a year earlier, with Marketplace enrollment falling sharply from approximately 713,000 to 267,000 members.

Despite the pressures, management reaffirmed full-year 2026 adjusted EPS guidance of $5.25 and left premium revenue guidance unchanged at approximately $42 billion. The quarter also included a non-cash impairment charge tied to the company's decision to exit its Medicare Advantage Prescription Drug (MAPD) product in 2027, part of a strategic shift to focus on dual-eligible members.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. For investors tracking names like Molina Healthcare, it offers a streamlined way to surface signals and monitor shifting conditions across the managed care sector. Explore the AI Screener to refine your research process today.

Market Reaction and Investor Sentiment

The market's initial response was cautious. Despite the double beat on earnings and revenue, shares of Molina Healthcare declined about 5.5% in after-hours trading following the release, suggesting that investors were more focused on the underlying margin squeeze than on the headline figures. A 52% drop in GAAP net income and a rising consolidated MCR signaled that the company is still absorbing higher medical costs and shrinking membership.

The muted reaction echoed the prior quarter, when an earnings beat was similarly overshadowed by concerns about the operating picture. Heading into this report, analyst sentiment had turned more cautious, with consensus estimates revised downward in the weeks before the release. The stock's decline after the print indicates that the market remains skeptical until there is clearer evidence that Medicaid margins are turning.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central question is whether Molina Healthcare can deliver the margin recovery that the market has already begun to price in. CEO Joseph Zubretsky indicated that the company is seeing an apparent plateauing of medical cost trend and that the strength of 2027 rate updates suggests Molina may be "likely observing the beginning of the turn in Medicaid margins." That commentary will be a key benchmark for investors in the quarters ahead.

Membership trends will remain critical. Medicaid enrollment has been declining industry-wide, and investors should watch whether that contraction stabilizes ahead of new work requirements taking effect in 2027. The company's strategic exit from its Medicare Advantage Prescription Drug product is also worth monitoring, as it reflects a deliberate narrowing of focus toward dual-eligible members.

Finally, cost management will be the defining factor. With the consolidated MCR still elevated, any further uptick in medical costs could quickly erode the thin margin between premiums and claims. Reaffirmed full-year guidance of $5.25 in adjusted EPS provides a floor for near-term expectations, but the trajectory of 2027 rates and medical cost trends will ultimately determine whether the anticipated recovery materializes. Investors will be watching upcoming earnings for confirmation that margins are improving rather than merely stabilizing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations